Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption by Young, David A et al.
Open Access
Available online http://arthritis-research.com/content/7/3/R503
R503
Vol 7 No 3 Research article
Histone deacetylase inhibitors modulate metalloproteinase gene 
expression in chondrocytes and block cartilage resorption
David A Young1,3, Rachel L Lakey2, Caroline J Pennington1, Debra Jones2, Lara Kevorkian1, 
Dylan R Edwards1, Timothy E Cawston2 and Ian M Clark1
1School of Biological Sciences, University of East Anglia, Norwich, UK
2Department of Rheumatology, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK
3Department of Rheumatology, University of Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK
Corresponding author: Ian M Clark, i.clark@uea.ac.uk
Received: 11 Nov 2004 Revisions requested: 23 Dec 2004 Revisions received: 7 Jan 2005 Accepted: 25 Jan 2005 Published: 22 Feb 2005
Arthritis Research & Therapy 2005, 7:R503-R512 (DOI 10.1186/ar1702)
This article is online at: http://arthritis-research.com/content/7/3/R503
© 2005 Young et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Cartilage destruction in the arthritides is thought to be mediated
by two main enzyme families: the matrix metalloproteinases
(MMPs) are responsible for cartilage collagen breakdown, and
enzymes from the ADAMTS (a disintegrin and metalloproteinase
domain with thrombospondin motifs) family mediate cartilage
aggrecan loss. Many genes subject to transcriptional control are
regulated, at least in part, by modifications to chromatin,
including acetylation of histones. The aim of this study was to
examine the impact of histone deacetylase (HDAC) inhibitors on
the expression of metalloproteinase genes in chondrocytes and
to explore the potential of these inhibitors as chondroprotective
agents. The effects of HDAC inhibitors on cartilage degradation
were assessed using a bovine nasal cartilage explant assay. The
expression and activity of metalloproteinases was measured
using real-time RT-PCR, western blot, gelatin zymography, and
collagenase activity assays using both SW1353
chondrosarcoma cells and primary human chondrocytes. The
HDAC inhibitors trichostatin A and sodium butyrate potently
inhibit cartilage degradation in an explant assay. These
compounds decrease the level of collagenolytic enzymes in
explant-conditioned culture medium and also the activation of
these enzymes. In cell culture, these effects are explained by the
ability of HDAC inhibitors to block the induction of key MMPs
(e.g. MMP-1 and MMP-13) by proinflammatory cytokines at both
the mRNA and protein levels. The induction of aggrecan-
degrading enzymes (e.g. ADAMTS4,  ADAMTS5, and
ADAMTS9) is also inhibited at the mRNA level. HDAC inhibitors
may therefore be novel chondroprotective therapeutic agents in
arthritis by virtue of their ability to inhibit the expression of
destructive metalloproteinases by chondrocytes.
Introduction
Articular cartilage is made up of two main extracellular-matrix
(ECM) macromolecules, namely, type II collagen and aggre-
can (a large, aggregating proteoglycan) [1,2]. The type II col-
lagen scaffold endows the cartilage with its tensile strength,
while the aggrecan, by virtue of its high negative charge, draws
water into the tissue, swelling against the collagen network,
and enabling the tissue to resist compression. Quantitatively
more minor components (e.g. types IX, XI, and VI collagens;
biglycan; decorin; cartilage oligomeric matrix protein; etc.)
also have important roles in controlling matrix structure and
organisation [2].
Normal cartilage ECM is in a state of dynamic equilibrium, with
a balance between synthesis and degradation. For the degra-
dative process, the major players are metalloproteinases that
degrade the ECM, and their inhibitors. Pathological cartilage
destruction can therefore be viewed as a disruption of this bal-
ance, favouring proteolysis.
The matrix metalloproteinases (MMPs) are a family of 23
enzymes in man that facilitate turnover and breakdown of the
ECM in both physiology and pathology. The MMP family con-
tains the only mammalian proteinases that can specifically
degrade the collagen triple helix at neutral pH. These include
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the 'classical' collagenases – MMP-1, -8, and -13 – and also
MMP-2 and MMP-14 (which cleave the triple helix with less
catalytic efficiency). The enzyme(s) responsible for cartilage
collagen cleavage in the arthritides remains open to debate
[3].
A second group of metalloproteinases, the ADAMTS (a disin-
tegrin and metalloproteinase domain with thrombospondin
motifs) family, consists of 19 members, including the so-called
'aggrecanases', currently ADAMTS-1, -4, -5, -8, -9, and -15 [4-
7]. Current data support the hypothesis that aggrecanases are
active early in the disease process, with later increases in
MMP activity (several MMPs can also degrade aggrecan), but
the exact enzyme(s) responsible for cartilage aggrecan
destruction at any stage in arthritis is unclear [3,8,9].
A family of four specific inhibitors, the tissue inhibitors of met-
alloproteinases (TIMPs), has been described. TIMPs are
endogenous inhibitors of MMPs and potentially of ADAMTSs
[10]. The ability of TIMP-1 to -4 to inhibit active MMPs is
largely promiscuous, though a number of functional differ-
ences have been uncovered. TIMP-3 appears to be the most
potent inhibitor of ADAMTSs, for example, with a subnanomo-
lar Ki against ADAMTS-4 [3].
Metalloproteinase activity is regulated at multiple levels,
including gene transcription. However, the role of chromatin
modification, and in particular acetylation, is little researched in
the metalloproteinase arena. The packaging of eukaryotic
DNA into chromatin plays an important role in regulating gene
expression. The DNA is wound round a histone octamer con-
sisting of two molecules each of histones H2A, H2B, H3, and
H4, to form a nucleosome [11]. This unit is repeated at inter-
vals of approximately 200 base pairs, with histone H1 associ-
ating with the intervening DNA. Nucleosomes are generally
repressive to transcription, hindering access of the transcrip-
tional apparatus [11]. However, two major mechanisms mod-
ulate chromatin structure to allow transcriptional activity: ATP-
dependent nucleosome remodellers such as the Swi/Snf com-
plex [12,13]; and the enzymatic modification of histones, via
acetylation, methylation, and phosphorylation [14-16].
Acetylation by histone acetyltransferases occurs on specific
lysine residues on the N-terminal tails of histones H3 and H4.
This neutralisation of positive charge leads to a loosening of
the histone:DNA structure, allowing access of the transcrip-
tional machinery; furthermore, the acetyl groups may associate
with and recruit factors containing bromodomains [11]. Many
transcriptional activators or coactivators have (or recruit) his-
tone acetyltransferase activity, giving a mechanism whereby
acetylation can be targeted at specific gene promoters
[15,16]. Conversely, histone deacetylases (HDACs) have also
been characterised. Hypoacetylation of histones associates
with transcriptional silence, and several transcriptional repres-
sors and corepressors have been identified that have (or
recruit) HDAC activity [17-19]. Nonhistone substrates of his-
tone acetyltransferases have also been described, for exam-
ple, p53, E2F, nuclear factor κB, Sp3, and c-Jun [20,21].
There are two families of HDACs, the NAD+-dependent, so-
called SIR2 family (sometimes called class III HDACs), and the
classical HDAC family. The classical HDACs can be grouped
into three classes (I, II, and IV) based on phylogeny [22]. Class
I HDACs (HDAC1, 2, 3, and 8) are related to yeast RPD3, and
class II HDACs (HDAC4, 5, 6, 7, 9, and 10) are more closely
related to yeast HDA1 [17]. HDAC11 alone represents class
IV, and HDAC11-related proteins have been described in all
eukaryotic organisms other than fungi [22]. Trichostatin A
(TSA) and sodium butyrate (NaBy), are HDAC inhibitors
[23,24] with a broad spectrum of activity against class I and II
HDACs, but not the SIR2 family. Addition of these reagents to
cells should therefore block histone deacetylation and result in
increased acetylation of histones on susceptible genes. The
prediction would be that this would lead to an increase in gene
expression, and this is largely borne out experimentally. How-
ever, there are many instances of HDAC inhibitors acting as
repressors of gene expression [25-29].
HDAC inhibitors have potent antiproliferative and pro-apop-
totic activities in cancer cells and this has led to the develop-
ment of specific inhibitors for cancer chemotherapy. Such
compounds are currently in both preclinical development and
clinical trials [30].
Two recent reports demonstrate that HDAC inhibitors modu-
late gene expression in synovial cells [31]. In an animal model
of rheumatoid arthritis (adjuvant arthritis), the expression of
tumour necrosis factor α (TNF-α) was inhibited and this led to
a reduction in synovial hyperplasia and joint swelling with
maintenance of joint integrity [31]. Similar results were
obtained in an autoantibody-mediated murine model [32].
However, no study has looked at the effect of these inhibitors
on cartilage. Here, we show for the first time that HDAC inhib-
itors repress the expression of several members of the metal-
loproteinase family in chondrocytes and block cartilage
destruction in an ex vivo model system. Hence, inhibition of
HDAC activity offers a potential therapeutic strategy to pre-
vent cartilage destruction in the arthritides.
Materials and methods
Cell culture
SW1353 human chondrosarcoma cells (ATCC, USA) were
routinely cultured in DMEM (Invitrogen, Paisley, UK) contain-
ing 10% fetal bovine serum (Invitrogen), 2 mM glutamine, 100
IU/ml penicillin, and 100 µg/ml streptomycin. Serum-free con-
ditions used identical medium without fetal bovine serum. For
assays, cells were grown to confluency, then starved of serum
for 24 hours before the addition of IL-1α (R&D Systems) (5 ng/
ml) and oncostatin M (OSM) (R&D Systems) (10 ng/ml) in the
absence or presence of HDAC inhibitors (TSA, 50 to 500 ng/Available online http://arthritis-research.com/content/7/3/R503
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ml, and NaBy, 1 to 10 mM) (Calbiochem, Nottingham, UK).
Experiments were performed in six-well plates (Nunc, Fisher
Scientific, Loughborough, UK) with all conditions in duplicate
or triplicate. To obtain primary human chondrocytes, fresh
human articular cartilage samples (from patients undergoing
hip or knee replacement surgery at the Norfolk and Norwich
University Hospital) were digested overnight in DMEM con-
taining 2 mg/ml of collagenase Type 1A (Sigma, Poole, UK).
The resulting cells were washed with PBS, resuspended in
DMEM containing 10% FCS and antibiotics as above, and
then plated at 1 × 106 cells in 75-cm2 flasks. At confluence,
cells were passaged and replated at 1:2 dilution.
RNA isolation and synthesis of cDNA
RNA was isolated from monolayer cultures using Trizol rea-
gent (Invitrogen). cDNA was synthesised from 1 µg of total
RNA using Superscript II reverse transcriptase (Invitrogen)
and random hexamers in a total volume of 20 µl according to
the manufacturer's instructions. cDNA was stored at -20°C
until use in downstream PCR.
RT-PCR
For quantitative real-time PCR, sequences and validation for
MMP  and  TIMP  primers and probes are as previously
described [33] and so are ADAMTS primers and probes [34].
In order to control against amplification of genomic DNA, prim-
ers were placed within different exons close to an intron/exon
boundary with the probe spanning two neighbouring exons
where possible. BLAST searches for all the primer and probe
sequences were also conducted to ensure gene specificity.
The 18 S ribosomal RNA gene was used as an endogenous
control to normalise for differences in the amount of total RNA
present in each sample; 18 S rRNA primers and probe were
purchased from Applied Biosystems (Warrington, UK).
Relative quantification of genes was performed using the ABI
Prism 7700 sequence detection system (Applied Biosystems)
in accordance with the manufacturer's protocol. PCR reac-
tions contained 5 ng of reverse transcribed RNA (1 ng for 18
S analyses), 50% TaqMan 2X Master Mix (Applied Biosys-
tems), 100 nM of each primer, and 200 nM of probe in a total
volume of 25 µl. Conditions for the PCR reaction were 2 min
at 50°C, 10 min at 95°C, and then 40 cycles each consisting
of 15 s at 95°C and 1 min at 60°C.
Conventional RT-PCR for collagen and aggrecan expression
was as previously described [35].
Cartilage degradation assay
Bovine nasal cartilage was cultured as previously described
[36]. Briefly, discs (approximately 2 mm in diameter by 1 to 2
mm thick) were punched from bovine nasal septum cartilage;
three discs per well in a 24-well plate were incubated over-
night in control, serum-free medium (DMEM containing 25 mM
HEPES, 2 mM glutamine, 100 µg/ml streptomycin, 100 IU/ml
penicillin, 2.5 µg/ml gentamicin, and 40 u/ml nystatin). Fresh
control medium with or without test reagents (each condition
in quadruplicate) was then added (day 0). Cartilage was incu-
bated until day 7 and supernates were harvested and replaced
with fresh medium containing the same test reagents as day 0.
On day 14, supernates were harvested and the remaining car-
tilage was digested with papain. The viability of cartilage
explants was assessed by measurement of lactate dehydroge-
nase (LDH) in the conditioned medium (CytoTox 96 assay,
Promega, Southampton, UK). Hydroxyproline release was
assayed as a measure of collagen degradation [37], and gly-
cosaminoglycan release was assayed as a measure of prote-
oglycan degradation [36]. Collagenase activity was
determined by the 3H-acetylated collagen diffuse fibril assay
using a 96-well plate modification [38] and a standard curve
and appropriate sample dilutions; one unit of collagenase
activity degraded 1 µg of collagen per minute at 37°C. APMA
(4-aminophenylmercuric acetate) was used to activate procol-
lagenases [38]. Statistical analysis was performed using Stu-
dent's t-test.
Gelatin zymography
Samples were electrophoresed under nonreducing conditions
by SDS–PAGE in 10% polyacrylamide gels copolymerised
with 1% gelatin. Gels were washed vigorously twice for 15
min in 2.5% Triton X-100 to remove SDS, then incubated
overnight in 50 mM Tris/HCl, pH7.5, 5 mM CaCl2 at 37°C.
Gels were then stained with Coomassie brilliant blue. Parallel
gels were incubated in buffers containing either 5 mM EDTA
or 2 mM 1,10-phenanthroline to show that lysis of gelatin was
due to metalloproteinase activity.
Western blotting
Samples of conditioned culture medium were precipitated
with an equal volume of ice-cold 10% w/v trichloroacetic acid.
Precipitates were resuspened in loading buffer and electro-
phoresed under reducing conditions by SDS–PAGE in 10%
polyacrylamide gels. Proteins were then transferred to an
Immobilon P membrane (Millipore, Watford, UK) and probed
with either rabbit anti-(human MMP-1), [39], sheep anti-
(human MMP-1) [40], or sheep anti-(human MMP-13) [40].
Results
Histone deacetylase inhibitors block cartilage 
resorption and concurrently decrease collagen- and 
gelatin-degrading proteolytic activities
The combination of IL-1α and OSM has previously been
shown to reproducibly and potently induce cartilage prote-
oglycan and collagen proteolysis both in vitro and  in vivo
[41,42]. The addition of TSA or NaBy to bovine nasal cartilage
explant culture stimulated to resorb with IL-1α and OSM
caused a dose-dependent (50 to 500 ng/ml TSA, 1 to 10 mM
NaBy) inhibition of both proteoglycan and collagen release (at
day 7 and 14 respectively) (Fig. 1). TSA is reported to have an
IC50 (median inhibitory concentration) in the nanomolar rangeArthritis Research & Therapy    Vol 7 No 3    Young et al.
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(50 ng/ml = 165 nM), but this does vary depending upon the
HDAC and assay used (e.g. [43]); NaBy is reported to have an
IC50 in themillimolar range. The need for TSA, a hydroxamate,
to penetrate the highly negatively charged cartilage matrix will
also raise the effective IC50 in the cartilage explant assay. The
time points of medium collection, days 7 and 14, are those at
which release of, respectively, proteoglycan and collagen are
reproducibly close to 100%, since proteoglycan release is an
earlier event in cartilage degradation. At these time points, pro-
teoglycan release showed less sensitivity to HDAC inhibitors
than collagen release, behaviour that may reflect its more rapid
kinetics. Indeed, in a preliminary experiment at day 3, where IL-
1α/OSM-induced proteoglycan release was approximately
50%, an increased sensitivity to HDAC inhibitors was seen
(data not shown). Lactate dehydrogenase release, used as a
measure of toxicity, was no greater in the presence of TSA or
NaBy (at any concentration) than in the comparator control
cultures (i.e. either without any addition or treated with IL-1α/
OSM) at either day 7 or day 14; furthermore, no dose-depend-
ent effects of TSA or NaBy on the release of lactate dehydro-
genase were observed (data not shown).
Figure 2a shows collagenase activity at day 14 in the absence
or presence of TSA, assayed in the conditioned medium from
the explant assay discussed above. Treatment with IL-1α and
OSM increased collagenase activity in the medium, and all col-
lagenases were in the active form (since the addition of the
procollagenase activator APMA did not lead to an increase in
activity). The additional presence of TSA at the lowest dose
(50 ng/ml) decreased the level of active collagenase, whereas
total collagenase was unchanged; that is, the percentage of
collagenase that was active was decreased (since the addition
of APMA led to increased activity in the assay, demonstrating
the presence of procollagenases). With increasing dose, TSA
decreased the level of both active and total collagenase; that
is, the total amount of collagenase in the medium was
decreased and the percentage of this enzyme(s) that was acti-
vated also decreased. Similar results were obtained using
NaBy (data not shown).
Figure 2b shows a gelatin zymogram of the day-14 medium
cartilage-explant-conditioned medium in the absence or pres-
ence of TSA. Unstimulated explants produce a low constitu-
tive level of gelatinolytic activity, which was probably due to
proMMP-2. The addition of IL-1α and OSM induced three
major gelatinolytic activities, which ran as poorly resolved dou-
blets (all activities shown were blocked by metalloproteinase
inhibitors EDTA and 1,10-phenanthroline, and were therefore
due to the action of metalloproteinases; see Materials and
methods). The largest of these probably equates to bovine
MMP-9 (both pro- and active); there was an induction and acti-
vation of MMP-2 and an induction of a lower-molecular-weight
activity that may represent collagenases MMP-1 and MMP-13,
but could include other MMPs, many of which have at least
some activity against gelatin. Both of the collagenases, and
Figure 1
Histone deacetylase inhibitors block cartilage glycosaminoglycan and  collagen loss induced by IL-1α/OSM Histone deacetylase inhibitors block cartilage glycosaminoglycan and 
collagen loss induced by IL-1α/OSM. Bovine nasal cartilage discs were 
cultured in the presence or absence of I/O (a combination of IL-1α and 
oncostatin M (OSM)) and a histone deacetylase inhibitor, either (a) I/O 
(1 ng/ml IL-1α, 10 ng/ml OSM) with trichostatin A (TSA) or (b) I/O (0.2 
ng/ml IL-1α, 2 ng/ml OSM) with sodium butyrate (NaBy). Cartilage was 
incubated until day 7 and supernates were harvested and replaced with 
fresh reagents until day 14. Glycosaminoglycan (GAG) release is 
shown as at day 7 and was assayed using the dimethylmethylene blue 
method. Collagen release is shown as at day 14 and was measured 
using an assay for hydroxyproline. Viability was assessed by measuring 
lactate dehydrogenase in the conditioned medium. Assays were per-
formed at least twice using quadruplicate samples; means ± standard 
deviations are represented. *P < 0.05, **P < 0.01, ***P < 0.001.
0
10
20
30
40
50
60
70
80
90
100
I/O - + - - - - + + + +
TSA (ng/ml) - - 50 100 250 500 50 100 250 500
**
***
***
%
G
A
G
r
e
l
e
a
s
e
0
10
20
30
40
50
60
70
80
90
100
500 250 100 50 500 250 100 50 - - TSA (ng/ml)
+ + + + - - - - + - I/O
*** ***
*** ***
%
c
o
l
l
a
g
e
n
r
e
l
e
a
s
e
0
10
20
30
40
50
60
70
80
90
100
I/O - + - - - + + +
NaBy (mM) - - 1 5 10 1 5 10
***
***
%
G
A
G
r
e
l
e
a
s
e
0
10
20
30
40
50
60
70
80
90
100
10 5 1 10 5 1 - - NaBy (mM)
+ + + - - - + - I/O
*
*** ***
%
c
o
l
l
a
g
e
n
r
e
l
e
a
s
e
(a)
(b)Available online http://arthritis-research.com/content/7/3/R503
R507
particularly MMP-13, have gelatinolytic activity [44,45], and
this would therefore be in agreement with the induction of col-
lagenase activity shown in Fig. 2. TSA at the lowest dose (50
ng/ml) caused a marked reduction in the lowest-molecular-
weight activity, while increasing doses reduced the activities
of all the gelatinolytic enzymes to background levels.
Histone deacetylase inhibitors modulate MMP gene 
expression
Using the SW1353 chondrosarcoma cell line as a model in
which to look at the regulation of metalloproteinase and TIMP
gene expression, we profiled the expression of all MMPs,
ADAMTSs, and TIMPs in cells stimulated with IL-1α and OSM
in the absence or presence of HDAC inhibitors at the doses
used for the cartilage explant experiments above. Figure 3a
shows typical responses for genes induced by IL-1α and
OSM. A number of genes – MMP1, MMP3, MMP7, MMP8,
MMP10,  MMP12,  MMP13,  ADAMTS4, and ADAMTS9  –
were robustly induced by the combination of IL-1α and OSM
(though both ADAMTS4 and ADAMTS5 were expressed only
at low levels in this cell line, with ADAMTS5 showing a weak
induction with IL-1α and OSM). Of these induced genes,
including ADAMTS5, all but ADAMTS4 showed repression by
both TSA and NaBy. ADAMTS4, while strongly induced by IL-
1α and OSM, was not repressed by either HDAC inhibitor in
this cell line. The expression of a number of genes (MMP2,
MMP9,  MMP16, and MMP19;  ADAMTS1,  ADAMTS2,
ADAMTS7,  ADAMTS12,  ADAMTS13, and ADAMTS20;
TIMP3) was unaffected by the HDAC inhibitors, whereas the
expression of several genes was induced by HDAC inhibitors
alone (MMP17,  MMP23,  MMP28;  ADAMTS15  and
ADAMTS17; TIMP2). The varying response to HDAC inhibi-
tors across the gene families also affirms that the compounds
are not simply showing a nonspecific toxicity.
In order to verify that the effects of HDAC inhibitors were not
specific to the SW1353 cell line, we undertook a similar exper-
iment on a subset of genes, using primary articular chondro-
cytes isolated from both knee and hip joint (i.e. from two
different donors). MMP1 and MMP13, the two major specific
collagenases, were strongly induced by IL-1α and OSM, and
this induction was repressed by both TSA (500 ng/ml) and
NaBy (10 mM) (Fig. 3b). MMP8 was expressed at much lower
levels in these cells but followed the same pattern of
responses (data not shown). The IL-1α and OSM induction of
MMP3 gene expression was only poorly repressed by HDAC
inhibitors in the primary chondrocytes (data not shown). In
these cells, ADAMTS4, ADAMTS5, and ADAMTS9 were all
induced by IL-1α and OSM and the induction was repressed
by HDAC inhibitors (Fig. 3c). These primary chondrocytes,
although grown in monolayer culture, still express type II colla-
gen and aggrecan at the passage at which this experiment
was performed.
Histone deacetylase inhibitors repress MMP protein 
expression and activity
In order to ascertain if changes at the level of steady-state
mRNA are mirrored at the protein level, we performed western
blots on the conditioned medium of SW1353 cells at a 24-
hour time point. Both MMP-1 and MMP-13 proteins were
Figure 2
HDAC inhibitors decrease collagenolytic and gelatinolytic activity from bovine nasal explants and block collagenase activation HDAC inhibitors decrease collagenolytic and gelatinolytic activity from bovine nasal explants and block collagenase activation. Conditioned media 
from cartilage assays (day 14) as in Fig. 1a were assayed (a) for collagenase activity in the presence or absence of 0.67 mM APMA, an activator of 
procollagenases (means ± standard errors of the mean), and (b) for gelatinase activity, using gelatin zymography. APMA, aminophenylmercuric ace-
tate; HDAC, histone deacetylase; I/O, a combination of IL-1α and OSM; MMP, matrix metalloproteinase; OSM, oncostatin M; TSA, trichostatin A.
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Figure 3
Histone deacetylase inhibitors abrogate IL-1α/OSM-induced expression of key metalloproteinase genes Histone deacetylase inhibitors abrogate IL-1α/OSM-induced expression of key metalloproteinase genes. Cells were starved of serum for 24 hours 
before stimulation with I/O, a combination of IL-1α (5 ng/ml) and oncostatin M (OSM) (10 ng/ml) for 6 hours in the absence or presence of either tri-
chostatin A (TSA) ((a) as shown or (b, c) 500 ng/ml) or NaBy ((a) as shown; (b, c) 10 mM). Total RNA was isolated and subjected to quantitative 
RT-PCR for expression of the genes (a, b) MMP1 and MMP13 and (c) ADAMTS4, ADAMTS5, and ADAMTS9. Data were normalised to the 18 S 
rRNA housekeeping gene; means and ranges are plotted. Absolute numbers are primer/probe-set-dependent and so cannot be compared between 
genes. (a) SW1353 chondrosarcoma cells; (b, c) primary human chondrocytes; (b) (inset) expression of COL2A1 and aggrecan by conventional 
RT-PCR. I/O, O/I, a combination of IL-1α and OSM; NaBy, sodium butyrate.
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potently induced by treatment with IL-1α and OSM and this
induction was repressed by both TSA and NaBy in the same
manner as the mRNA (Fig. 4). Two different anti-MMP-1 anti-
bodies (one raised in rabbits [39] and one raised in sheep
[40]) cross-react with a protein of slightly lower Mr than MMP-
1 in the SW1353-conditioned medium. The identity of this
protein is unknown, but its expression has been previously
documented [40] (though misinterpreted as that of active
MMP-1), it is unaltered by the stimuli used, and it is not present
in conditioned medium from primary chondrocytes (data not
shown).
Gelatin zymography showed some induction of MMP-9, as
well as multiple bands at around the Mr of the collagenases
that are induced by IL-1α/OSM and repressed by the addi-
tional presence of HDAC inhibitors in this system.
Discussion
HDAC inhibitors are currently being developed as cancer ther-
apeutics, largely by virtue of their impact upon the cell cycle
and apoptosis [30] in transformed cells. However, it is clear
that such compounds have pleiotropic effects on gene expres-
sion. Conceptually, the action of HDAC inhibitors leading to an
increase in histone acetylation should induce expression of
susceptible genes, but in fact, many instances of a repression
of gene expression have been reported [25-29]. In yeast, the
ability of TSA to down-regulate some genes very rapidly
(within 15 min of exposure) suggests that HDACs may func-
tion as direct transcriptional activators in some instances [25].
The combination of IL-1 and oncostatin M potently induces
both cartilage aggrecan and collagen degradation in vitro and
in vivo [41,42] and these factors induce the expression of a
number of metalloproteinase genes in chondrocyte cell lines
[46]. The addition of either of two chemically distinct HDAC
inhibitors to cartilage explant cultures blocks IL-1/OSM-
induced cartilage catabolism with a decrease in collagenolytic
activity in the conditioned culture medium. TSA and NaBy
themselves do not directly inhibit collagenase activity, and it
therefore seemed likely that they were altering expression of
genes encoding the metalloproteinases or their inhibitors.
Using SW1353 chondrosarcoma cells, which are known to
respond to IL-1/OSM [40], and primary chondrocytes, real-
time RT-PCR gene profiling showed that the expression of a
number of MMP and ADAMTS genes was robustly induced by
IL-1/OSM and repressed by HDAC inhibitors. In SW1353
cells, MMP2 is not induced by IL-1/OSM nor altered by HDAC
inhibitors; MMP9  is weakly induced by IL-1/OSM and this
induction is repressed by HDAC inhibitors. In primary
chondrocytes,  MMP2  expression is induced approximately
twofold to fourfold by IL-1/OSM, but is not then repressed by
HDAC inhibitors. This is in marked contrast to the zymography
data from cartilage explants and suggests a role for cell–matrix
interactions in mediating the effects of IL-1/OSM on these
gelatinase genes.
Previous studies have shown that TSA represses MMP2
expression in mouse 3T3 fibroblasts but not in human HT1080
fibrosarcoma cells [47,48], showing that the effects of HDAC
inhibitors on MMP expression are specific to cell type and
potentially to species. In primary chondrocytes, the effects of
HDAC inhibitors on the collagenases (MMP1,  MMP8,
MMP13) mirrored that seen in the SW1353 cell line; however,
MMP3, though strongly induced by IL-1/OSM in primary
chondrocytes, was not significantly repressed by HDAC inhib-
itors. The ability of HDAC inhibitors to repress MMP expres-
sion at the mRNA level is reiterated at the protein level, as we
have shown for MMP-1 and MMP-13. In primary chondro-
cytes, the aggrecanases ADAMTS4,  ADAMTS5, and
ADAMTS9 were also strongly induced by IL-1/OSM and were
repressed by HDAC inhibitors. In SW1353 cells, both
ADAMTS4 and ADAMTS5 genes are expressed at a very low
level and are therefore difficult to measure; ADAMTS9, how-
ever, is expressed robustly, is induced by IL-1/OSM, and is
repressed by HDAC inhibitors, with a pattern similar to that
shown for MMP1 and MMP13 in Fig. 3a. This repression of
aggrecanase gene expression is consistent with the ability of
HDAC inhibitors to inhibit cartilage glycosaminoglycan release
as shown in Fig. 1.
HDAC inhibitors appear to affect not only the expression of
collagenolytic and gelatinolytic MMPs, but also their activation
(Fig. 2). It is known that activation of procollagenases is a key
control point in cartilage resorption and this can be mediated
by cascades within the MMP family (e.g. MMP-3 can activate
procollagenases) or via the action of other enzyme families
(e.g. plasmin, a serine proteinase) [49,50]. Therefore, it is likely
that HDAC inhibitors repress the expression of one or more
Figure 4
Histone deacetylase inhibitors repress matrix metalloproteinase (MMP)  protein expression and activity Histone deacetylase inhibitors repress matrix metalloproteinase (MMP) 
protein expression and activity. Cells were starved of serum for 24 
hours before stimulation with I/O, a combination of IL-1α (5 ng/ml) and 
oncostatin M (10 ng/ml), for 24 hours in the absence or presence of tri-
chostatin A (TSA) (500 ng/ml) or sodium butyrate (NaBy) (10 mM). 
Conditioned media were subjected to western blot analysis using a rab-
bit anti-(human MMP-1) antibody or a sheep anti-(human MMP-13) anti-
body or gelatin zymography, as described in Materials and methods.
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key procollagenase activators in cartilage; study of, for
example, plasminogen or plasminogen activator expression
might be informative.
Since almost all metalloproteinase genes that are robustly
induced by IL-1/OSM are then repressed by the further addi-
tion of HDAC inhibitors, a likely explanation is the ability of
HDAC inhibitors to interfere with IL-1/OSM signalling. Since
these cytokines are proinflammatory mediators, action via
nuclear factor κB is one possibility; however, the literature
shows that TSA actually potentiates signalling through this
pathway [51,52]. OSM, an IL-6 family cytokine, signals
through the STAT pathway; recent reports show that HDAC
activity plays an essential role in at least STAT1 signalling, and
that TSA can therefore abrogate STAT1-induced gene expres-
sion [53,54]. We (TEC and co-workers) have previously
reported that at least STAT3 signalling indirectly mediates the
ability of IL-1/OSM to induce MMP1 gene expression [55].
Dissecting the pathways that mediate the impact of HDAC
inhibitors on induction of metalloproteinase genes by IL-1/
OSM will therefore be one focus of our future work.
Two previous reports using the rodent models of rheumatoid
arthritis (rat adjuvant arthritis and murine autoantibody-medi-
ated arthritis) showed that HDAC inhibitors (TSA, phenylbu-
tyrate, or FK228) block proliferation of cultured synovial
fibroblasts with accompanying up-regulation of cell cycle
inhibitors (p16INK4 and p21Cip1) [31,32]. In vivo, this was mir-
rored with inhibition of synovial hyperplasia and pannus forma-
tion, leading to abrogation of cartilage destruction in the
models. Interestingly, the HDAC inhibitors also repressed
expression of TNF-α a n d / o r  I L - 1  i n  s y n o v i a l  t i s s u e .  T h e s e
reports suggest that HDAC inhibitors may represent a new
class of compounds for treatment of rheumatoid arthritis
[31,32]. Anti-inflammatory properties of another HDAC inhibi-
tor, suberoylanilide hydroxamic acid (SAHA), have also been
demonstrated in vitro and in vivo, via the suppression of proin-
flammatory cytokines such as TNF-α and IL-1 [56,57].
All of these papers suggest a major effect of HDAC inhibitors
in repressing the production of proinflammatory cytokines. Our
current data show for the first time that HDAC inhibitors can
also function as potent repressors of key metalloproteinase
expression in cartilage and chondrocytes and thus block carti-
lage breakdown. This suggests they may have wider therapeu-
tic use outside of just the inflammatory arthritides, as
chondroprotective agents. It should be underlined that where
the action of HDAC inhibitors is to repress the induced expres-
sion of MMP or ADAMTS genes, this expression is pushed
back to control levels but not to zero. This may be important in
any therapeutic use of HDAC inhibitors, since normal connec-
tive tissue turnover may therefore be unimpaired (though it
should also be noted that some MMP and ADAMTS genes are
induced by HDAC inhibitors). Our future work will identify the
HDAC(s) that have an effect on metalloproteinase expression
and identify the mechanism by which this occurs. This has the
potential to allow the design and use of compounds specific
for one HDAC (or a small number of HDACs), which may be
crucial in avoiding toxicity in vivo.
Conclusion
HDAC inhibitors can repress the expression and activity of
matrix-degrading proteinases in chondrocytes and cartilage.
These compounds, in preclinical development as chemothera-
peutic agents, also have strong potential as chondroprotective
agents.
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